October 24, 2025

Asthma Exacerbations Equal With Two Biologics

Matched asthma cohorts show identical exacerbation rates with differing safety profiles.

Conexiant

October 23, 2025

Chest Pain & Shock After a Tuna Sandwich: What’s Your Diagnosis?

A 30-year-old man with no prior medical history developed cardiogenic shock shortly after eating a tuna sandwich. He experienced central, burning chest pain, diaphoresis, and generalized pruritus. His pain worsened with breathing and did not respond to nitroglycerin.

Conexiant

October 23, 2025

Nutritional IBD screening tools ranked

Single-center cohort finds MIRT most sensitive at predicting malnutrition or low Fat-Free Mass Index within six months in patients in remission with IBD; SaskIBD-NR shows the highest accuracy for GLIM-defined malnutrition and for low Fat-Free Mass Index.

Conexiant

October 23, 2025

Is the Estradiol Ring Losing Strength Early?

Patients reported return of vasomotor symptoms before the 3-month mark in real-world use. 

Conexiant

October 19, 2025

ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.

Dana-Farber

October 14, 2025

What Happened at Meeting on the Mesa 2025?

This year’s Meeting on the Mesa showed that cell and gene therapy is no longer defined by hype, but by hard work– from digital manufacturing to creative funding models and policy alignment.

The Medicine Maker

October 13, 2025

Join Roswell Park Revolutionaries for Cell Therapy Symposium at ASH

Renier Brentjens, MD, PhD, and Marco Davila, MD, PhD, will host a satellite symposium during this year’s ASH meeting to discuss the evolving landscape of CAR T-cell therapy.

Roswell Park Comprehensive Cancer Center

October 13, 2025

Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025

Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.

Dana-Farber

October 10, 2025

Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas

“Surgical oncologists play a pivotal role in the care of patients with many types of cancer, often serving as the initial point of contact for health-care delivery. With this research, we sought to pr...

The ASCO Post